TYRA:NASDAQTyra Biosciences, Inc. Analysis
Data as of 2026-09-01 - not real-time
$25.03
Latest Price
8/10Risk
Risk Level: High
Executive Summary
At $25.03, Tyra Biosciences, Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. It has lost 19.4% over the past 30 days. Relative strength is 37.2 — approaching oversold — and the MACD signal is bullish. The recent range runs from support at $24.17 up to resistance at $32.99.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 103.0% above today's level.
Risk scores 8 out of 10, which is high for this asset class. With 30-day volatility of 80.0%, a beta of 0.63 and a maximum drawdown of 37.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 3 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 103.0% above today's level.
Risk scores 8 out of 10, which is high for this asset class. With 30-day volatility of 80.0%, a beta of 0.63 and a maximum drawdown of 37.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 3 out of 10.
Top Market Events
Updated Aug 4, 2026 0 \- Initial Ph2 data from SURF302 expected in September 2026 n 40 enrolled to date - \- Initial...Yahoo Finance27dTyra Biosciences Reports Second Quarter 2026 Financial Results and Recent HighlightsThe above button...Intelligent Investor2monTyra Biosciences NASDAQ: TYRA - Related ResearchTyra Biosciences Inc is a clinical-stage...
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 30.10
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 30.10
- Analyst targets imply +103.0% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- Analyst targets imply +103.0% versus the current price
- Negative return on equity of -45.3%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
P/E Ratio-8.4
ROE-45.31%
ROA-28.46%
Debt/Equity1.58
P/B Ratio4.2
Op. Cash Flow$-109651000
Free Cash Flow$-63067124
Industry P/E30.4
Technical Analysis
TrendBearish
RSI37.2
Support$24.17
Resistance$32.99
MA 20$26.23
MA 50$29.40
MA 200$30.10
MACDBullish
VolumeDecreasing
Fear & Greed Index94.79
Valuation
Target Price$50.82
Upside/Downside103.03%
GradeFair
TypeGrowth
Risk Assessment
Beta0.63
Volatility79.96%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.